VZV Pneumonitis Treatment
Treat VZV pneumonitis with intravenous acyclovir 10-15 mg/kg three times daily for 10-14 days, starting immediately upon clinical suspicion without waiting for confirmatory testing.
Primary Treatment Approach
The cornerstone of VZV pneumonitis management is high-dose intravenous acyclovir, recognizing that VZV is significantly less sensitive to acyclovir than HSV 1.
Dosing Strategy
- Standard dose: 10 mg/kg IV three times daily
- Higher dose: 15 mg/kg IV three times daily can be considered if renal function is normal, given VZV's reduced acyclovir sensitivity 1
- Duration: 10-14 days, with longer courses needed in immunocompromised patients 1, 2
- Critical caveat: Monitor renal function frequently and adjust doses accordingly; most clinicians use the 10 mg/kg dose to balance efficacy with nephrotoxicity risk 1
Timing is Critical
Start treatment immediately based on clinical presentation—do not delay for laboratory confirmation. The evidence shows successful outcomes even when treatment is initiated after 72 hours, though earlier is better 2. Case reports demonstrate that delayed acyclovir therapy can still be effective in severe disseminated VZV with pneumonitis 2.
Adjunctive Corticosteroid Therapy
Consider adding corticosteroids (prednisolone 60-80 mg daily for 3-5 days) in VZV pneumonitis, particularly if there is evidence of vasculitic involvement or severe inflammatory response 1.
The rationale is that VZV-related lung disease has a significant immune-mediated inflammatory component beyond direct viral cytopathology 1. However, the evidence for corticosteroids remains limited and somewhat controversial—they reduce inflammation but have immunomodulatory effects that could theoretically facilitate viral replication 1.
Stronger indication for steroids: If imaging or clinical features suggest vasculopathy or stroke-like episodes accompanying the pneumonitis 1, 3.
Special Populations
Immunocompromised Patients
- Require prolonged courses of IV acyclovir beyond the standard 10-14 days 1
- Consider higher doses (15 mg/kg) if tolerated
- More aggressive monitoring for treatment failure
Pregnant Women
- VZV pneumonitis in pregnancy carries extremely high mortality risk
- Do not withhold acyclovir—maternal benefit outweighs theoretical fetal risk
- Zoster immune globulin within 96 hours of exposure for prophylaxis in susceptible pregnant women 4
Neonates
- Standard treatment is acyclovir
- If acyclovir unavailable: Ganciclovir 5 mg/kg every 12 hours has been used successfully as a life-saving alternative 5
- Add IVIG 400 mg/kg daily for 3 days in severe neonatal cases 5
Supportive Care Essentials
- ICU-level monitoring for patients with respiratory distress 1
- Mechanical ventilation as needed—do not hesitate to provide maximum ventilatory support 6
- Aggressive management of hypoxemia and ARDS if it develops 7
- Stop or reduce immunosuppressive agents (particularly mycophenolate) in transplant recipients while increasing corticosteroid coverage 2
Common Pitfalls to Avoid
- Waiting for PCR confirmation: Start treatment empirically based on clinical presentation (vesicular rash + pneumonia)
- Using oral acyclovir: VZV pneumonitis requires IV therapy due to severity and bioavailability concerns
- Underdosing: Remember VZV needs higher doses than HSV infections
- Premature discontinuation: Complete the full 10-14 day course even if clinical improvement occurs earlier
- Ignoring renal function: Acyclovir is nephrotoxic—monitor creatinine and adjust doses accordingly
Monitoring Treatment Response
- Clinical improvement in respiratory symptoms within 48-72 hours
- Resolution of fever
- Improvement in oxygen requirements and inflammatory markers (CRP, WBC)
- Crusting of skin lesions
- Normalization of chest imaging findings (though this lags clinical improvement)
Alternative Agents
Foscarnet can be used for acyclovir-resistant VZV, though this is rare in pneumonitis cases and typically seen only in severely immunocompromised patients with prior prolonged acyclovir exposure 1.